Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.

Antimicrobial agents and chemotherapy - 1 Dec 2000

Sindelar G, Zhao X, Liew A, Dong Y, Lu T, Zhou J, Domagala J, Drlica K

Abstract excerpt

Mutant prevention concentration (MPC) has been proposed as a new measure of antibiotic potency by which the ability to restrict selection of resistant mutants is evaluated. To determine whether MPC provides potency information unavailable from the more customary measurement of the MIC, 18 fluoroquinolones were examined for their ability to block the growth of Mycobacterium smegmatis and to select resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Ciprofloxacin
Share to DNA Gyrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type II

Share to Drug Resistance, Microbial

Share to Mycobacterium smegmatis

Share to Structure-Activity Relationship

Share to Topoisomerase II Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 11083637
DOI: 10.1128/AAC.44.12.3337-3343.2000
PMCID: PMC90202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.PMID 11083637Read ↗

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.Semantic proximity Read ↗

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Semantic proximity Read ↗

Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections.Semantic proximity Read ↗

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Semantic proximity Read ↗

Therapeutic options in an era of decreasing antimicrobial susceptibility.Semantic proximity Read ↗

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.Semantic proximity Read ↗

Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.Semantic proximity Read ↗

Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.